Key facts
- It has raised $4.3M across 2 recorded rounds; the latest was Seed Round ($1.0M) in Oct 2020.
- Notable investors include US National Science Foundation, MassVentures, Beacon Angels, Maroon Venture Partners, Massachusetts Medical Device Development Center — 7 tracked in total.
- Theromics has filed 4 Form Ds with the SEC since 2018, most recently May 2023 ($1.1M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Theromics
Funding rounds
2 roundsAbout Theromics
Developer of a thermal accelerant gel designed to enhance the transmission of thermal energy through the tissue during ablation. The company's thermal accelerant gel accelerates the thermal effects of tissue ablation by increasing the speed and volume of thermal treatment and blocks heat penetration, thus protecting critical tissue and structures for a personalized ablation zone, enabling physicians to improve thermal ablation in human health and disease.
- Sector
- Healthcare
- HQ
- West Bridgewater, MA, United States
- Founded
- 2016
- Employees
- 10
- Website
- theromicsinc.com/
- Ownership
- Privately Held (backing)
Theromics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Theromics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Theromics in its N-PORT filings yet. We sweep new filings monthly.